Italy Viral Vectors Plasmid DNA Manufacturing Market

ID: MRFR/MED/50128-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026
Italy Viral Vectors and Plasmid DNA Manufacturing Market Research Report By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, Infectious Disease), By Application (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research), By Workflow (Upstream Processing, Downstream Processing) and By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) -Forecast to 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Italy Viral Vectors Plasmid DNA Manufacturing Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)11.99%
2024 Market Size$ 5 Million
2025 Market Size$ 5.66 Million
2035 Market Size$ 17.38 Million

Key Players

MolMed S.p.A.
Genenta Science S.p.A.
Genoa Biopharma S.r.l.
Erytech Pharma S.A.
Adenoviral Therapeutics
Viralgen Vector Core
Trends
  • Increased Investment in Biotechnology
  • Regulatory Support for Gene Therapies
  • Collaboration Between Academia and Industry
Opportunities
  • Growing Demand for Gene Therapies
  • Supportive Regulatory Environment
  • Increased Public and Private Investment
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Gene Therapy
      2. 4.1.2 Vaccine Development
      3. 4.1.3 Cell Therapy
      4. 4.1.4 Oncology
      5. 4.1.5 Genetic Research
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Pharmaceutical Companies
      2. 4.2.2 Biotechnology Firms
      3. 4.2.3 Research Institutions
      4. 4.2.4 Academic Organizations
    3. 4.3 Healthcare, BY Type of Vector (USD Million)
      1. 4.3.1 Adenoviral Vectors
      2. 4.3.2 Lentiviral Vectors
      3. 4.3.3 Adeno-Associated Viral Vectors
      4. 4.3.4 Retroviral Vectors
    4. 4.4 Healthcare, BY Scale of Production (USD Million)
      1. 4.4.1 Small Scale
      2. 4.4.2 Medium Scale
      3. 4.4.3 Large Scale
    5. 4.5 Healthcare, BY Technology Used (USD Million)
      1. 4.5.1 Transfection
      2. 4.5.2 Electroporation
      3. 4.5.3 Viral Packaging
      4. 4.5.4 Microinjection
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 MolMed S.p.A. (IT)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Genenta Science S.p.A. (IT)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Genoa Biopharma S.r.l. (IT)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Erytech Pharma S.A. (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Adenoviral Therapeutics (IT)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Viralgen Vector Core (ES)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 SIRION Biotech GmbH (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 CureVac N.V. (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 ITALY MARKET ANALYSIS BY APPLICATION
    3. 6.3 ITALY MARKET ANALYSIS BY END USE
    4. 6.4 ITALY MARKET ANALYSIS BY TYPE OF VECTOR
    5. 6.5 ITALY MARKET ANALYSIS BY SCALE OF PRODUCTION
    6. 6.6 ITALY MARKET ANALYSIS BY TECHNOLOGY USED
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VECTOR, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VECTOR, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY TECHNOLOGY USED, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY TECHNOLOGY USED, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VECTOR, 2026-2035 (USD Million)
      4. 7.2.4 BY SCALE OF PRODUCTION, 2026-2035 (USD Million)
      5. 7.2.5 BY TECHNOLOGY USED, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Italy Viral Vectors Plasmid DNA Manufacturing Market Segmentation

Italy Viral Vectors Plasmid DNA Manufacturing Market By Application (USD Million, 2026-2035)

  • Gene Therapy
  • Vaccine Development
  • Cell Therapy
  • Oncology
  • Genetic Research

Italy Viral Vectors Plasmid DNA Manufacturing Market By End Use (USD Million, 2026-2035)

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Institutions
  • Academic Organizations

Italy Viral Vectors Plasmid DNA Manufacturing Market By Type of Vector (USD Million, 2026-2035)

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Adeno-Associated Viral Vectors
  • Retroviral Vectors

Italy Viral Vectors Plasmid DNA Manufacturing Market By Scale of Production (USD Million, 2026-2035)

  • Small Scale
  • Medium Scale
  • Large Scale

Italy Viral Vectors Plasmid DNA Manufacturing Market By Technology Used (USD Million, 2026-2035)

  • Transfection
  • Electroporation
  • Viral Packaging
  • Microinjection

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035